REGENXBIO (NASDAQ:RGNX) is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.
In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology. These collaborations leverage the company’s vector engineering expertise to create bespoke gene therapies across multiple therapeutic areas. Through such alliances, REGENXBIO gains access to complementary development resources, while partners benefit from its deep knowledge of AAV vector design and scalable manufacturing processes.
Founded in 2012 and headquartered in Rockville, Maryland, REGENXBIO operates a state‐of‐the‐art manufacturing facility to support both clinical and commercial production of AAV vectors. The company’s leadership team comprises industry veterans with extensive experience in gene therapy research, development and regulatory affairs. REGENXBIO’s scientific advisory board includes academic and clinical experts who guide vector selection, preclinical study design and clinical trial strategy.
REGENXBIO continues to expand its global footprint through clinical trial sites in North America, Europe and Asia, reflecting its commitment to bringing novel gene therapies to patients worldwide. By harnessing the NAV AAV platform’s versatility and safety profile, the company seeks to deliver one‐time treatments that have the potential to transform care for individuals living with severe genetic and ocular diseases.
